2025 ASCO GU 摘要标题公布！速览泌尿肿瘤“中国之声”|讲者|医学|北京大学肿瘤医院|四川大学华西医院

分享至

前言

2025年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO GU）将于2月13日至15日在加利福尼亚州旧金山召开，旨在向全球肿瘤学者传递国际泌尿肿瘤领域的最新研究进展。目前，大会官网已披露了摘要标题，医脉通特此整理相关摘要，希望与广大读者共同预瞻那些即将在国际舞台上奏响的中国强音。

Oral Abstract Session

摘要号：665

Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial

维迪西妥单抗联合特瑞普利单抗新辅助治疗HER2表达的肌层浸润性膀胱癌（MIBC）患者：II 期 RC48-C017 试验的最新疗效和安全性结果

讲者：盛锡楠北京大学肿瘤医院

General Session

摘要号：657

Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study

Nectin-4 靶向 ADC，SHR-A2102，用于治疗晚期或转移性尿路上皮癌患者：一项 1 期研究

讲者：唐碧霞北京大学肿瘤医院

Rapid Oral Abstract Session

摘要号：443

Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study

仑伐替尼联合替雷利珠单抗作为晚期富马酸水合酶缺陷型肾细胞癌的一线治疗：一项单中心、单臂、II 期研究

讲者：孔文上海交通大学医学院附属仁济医院

Poster Session

前列腺癌

摘要号：47

The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC

讲者：董柏君上海交通大学医学院附属仁济医院

摘要号：78

The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer

讲者：Qian Wang 四川大学华西医院

摘要号：103

Clinical features and prognostic value of CDK12 mutation in prostate cancer patients

讲者：董柏君上海交通大学医学院附属仁济医院

摘要号：161

Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC)

讲者：李锴文中山大学孙逸仙纪念医院

摘要号：214

The prognostic significance of circulating tumor DNA in prostate cancer: A systematic review and meta-analysis

讲者：Haolin Liu 四川大学华西医院

摘要号：325

Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021

讲者：Xianghong Zhou 四川大学华西医院

摘要号：328

An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations

讲者：张阁钧中国医科大学第一附属医院

摘要号：333

Interpretable machine learning for prostate biopsy: Cohort study

讲者：Jindong Dai 四川大学华西医院

摘要号：340

Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis

讲者：Qiyou Wu 四川大学华西医院

摘要号：390

Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis

讲者：Qihao Wang 四川大学华西医院

摘要号：404

Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study

讲者：Xiaoyang Liu 四川大学华西医院

摘要号：406

Chimeric RNA landscape in the Chinese population and the role of SFT2D2-TBX19 in prostate cancer progression

讲者：Qiong Wang 南方医科大学南方医院

摘要号：411

The impact of neoadjuvant therapy on the formation of tertiary lymphatic structures and the distinct prognosis in prostate cancer

讲者：Yunfei Yu 四川大学华西医院

摘要号：423

Assessment of the proficiency of ChatGPT-4o in an image-based robot-assisted radical prostatectomy scenario

讲者：Jiakun Li 四川大学华西医院

摘要号：TPS278

Efficacy and safety of organoid-based drug sensitivity screening to guide the treatment of mCRPC patients progressed after first-line treatment

讲者：Diwei Zhao 中山大学肿瘤防治中心

摘要号：TPS292

A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in metastatic hormone sensitive prostate cancer patients with HRR gene mutation: Updated analysis of PROact

讲者：邱雪峰南京鼓楼医院

摘要号：TPS299

Tislelizumab in combination with abiraterone/enzalutamide for metastatic castration-resistant prostate cancer with intraductal adenocarcinoma of the prostate after progression on prior androgen receptor pathway inhibitor

讲者：Qiyu Zhu 四川大学华西医院

摘要号：TPS307

Circulating tumor DNA (ctDNA) monitoring in the assessment and prediction of the efficacy of PARP inhibitors (PARPi)

讲者：Diwei Zhao 中山大学肿瘤防治中心

尿路上皮癌

摘要号：673

Postoperative adjuvant treatment of HER2 overexpression in upper urinary tract urothelial carcinoma with the combination of disitamab vedotin and toripalimab: A real-world retrospective study

讲者：张顺南京鼓楼医院

摘要号：688

Predictive value of neoadjuvant therapy combined with VI-RADS re-scoring in bladder preservation for muscle-invasive bladder cancer

讲者：袁方重庆大学肿瘤医院

摘要号：703

Intravesical gemcitabine and docetaxel combined with intravenous tislelizumab as a durable strategy for high-risk non–muscle-invasive bladder cancer

讲者：xiaobao chen 福建医科大学附属协和医院

摘要号：710

Effectiveness and safety of RC48-ADC in combination with toripalimab as neoadjuvant treatment in HER2-positive muscular invasive urothelial bladder cancer patients

讲者：李成龙武汉大学人民医院

摘要号：713

First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq

讲者：王晶晶中南大学湘雅二医院

摘要号：721

Modified transurethral resection of bladder tumors: A comparison study of chemotherapy-enhanced endoscopic submucosal en bloc dissection versus conventional resection

讲者：Xi Liu 辽宁省肿瘤医院

摘要号：726

Efficacy and safety of disitamab vedotin combined with toripalimab as neoadjuvant treatment for patients with locally advanced muscle-invasive bladder cancer: A mono-institutional retrospective study

讲者：Geng Zhang 第四军医大学西京医院

摘要号：729

Survival impact of concomitant squamous differentiation in upper tract urothelial carcinoma patients receiving adjuvant chemotherapy

讲者：Jianjun Ye 四川大学华西医院

摘要号：733

A retrospective real-world study of disitamab vedotin combined with tislelizumab versus chemotherapy in patients with previously untreated metastatic urothelial carcinoma

讲者：Han Se 包头医学院

摘要号：763

Phase Ib/II clinical trial of oncolytic virus intravesical irrigation for preventing recurrence after TURBT in patients with recurrent high-risk NMIBC

讲者：关有彦中国医学科学院肿瘤医院

摘要号：767

PUNCH01: Interim results from a phase II study of intra‑arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)

讲者：王宗任中山大学附属第一医院

摘要号：772

Impact of adjuvant intraarterial chemotherapy on survival for patients with stage IIIA-IIIB bladder urothelial carcinoma after radical cystectomy: An open-label, prospective, randomized clinical trial

讲者：Zhaohui Zhou 中山大学肿瘤防治中心

摘要号：775

Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study

讲者：沈益君复旦大学附属肿瘤医院

摘要号：784

Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical transurethral resection of bladder tumor/partial cystectomy: A prospective, phase II study

讲者：曹明上海交通大学医学院附属仁济医院

摘要号：786

Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02)

讲者：沈亚丽四川大学华西医院

摘要号：787

Safety and efficacy of intravesical bacillus Calmette-Guerin instillation for superficial recurrence following bladder-sparing therapy of muscle invasive bladder cancer

讲者：Gan Du 中国医学科学院肿瘤医院

摘要号：789

Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa)

讲者：卞晓洁复旦大学附属肿瘤医院

摘要号：790

Efficacy and safety of fexagratinib (Fexa) in Chinese patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) harboring FGF receptor (FGFR) genetic alterations

讲者：卞晓洁复旦大学附属肿瘤医院

摘要号：791

Kidney-sparing approach for selected localized high-risk upper tract urothelial carcinoma: A pilot study combining endoscopic thulium laser ablation with perioperative disitamab vedotin and immune checkpoint inhibitors

讲者：Jianjun Ye 四川大学华西医院

摘要号：794

Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift

讲者：Zeyu Chen 四川大学华西医院

摘要号：795

A multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03)

讲者：张朋四川大学华西医院

摘要号：796

Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study

讲者：叶定伟复旦大学附属肿瘤医院

摘要号：805

Safety and efficacy of bladder preservation therapy for very high-risk non-muscle-invasive bladder cancer: A single-center, single-arm prospective study (CIP-1)

讲者：袁方重庆大学肿瘤医院

摘要号：812

Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study

讲者：毕新刚中国医学科学院肿瘤医院

摘要号：829

Comprehensive investigation of CPSF3's role in the progression of bladder cancer

讲者：Zhiyang Ma 上海交通大学医学院附属瑞金医院

摘要号：837

Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle-invasive bladder cancer (MIBC)

讲者：曹煜东北京大学肿瘤医院

摘要号：839

Discordance in HER2 expression in primary and recurrent/metastatic lesions of upper tract urothelial carcinoma: A study focusing on temporal heterogeneity

讲者：Jianjun Ye 四川大学华西医院

摘要号：841

Pathological subclassification of T3 upper tract urothelial carcinoma: Complementary evidence for existing guidelines

讲者：Lei Zheng 四川大学华西医院

摘要号：844

Use of urinary cell-free DNA methylation assay to identify tumor fraction for early detection and recurrence monitoring in urothelial carcinoma

讲者：赵焕中国医学科学院肿瘤医院

摘要号：846

Use of urinary cell-free DNA fragmentomics in urothelial carcinoma diagnosis

讲者：赵焕中国医学科学院肿瘤医院

摘要号：852

Protein analysis of urachal carcinoma tissue based on different antibody-drug conjugate therapeutic targets

讲者：Tian Han 中国医学科学院肿瘤医院

摘要号：854

Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer

讲者：Xi Zheng南京鼓楼医院

摘要号：868

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy

讲者：JINCHANG WEI 北京大学肿瘤医院

摘要号：TPS894

Formula-01: A phase Ⅱ study of disitamab vedotin (RC48) intravenous injection combined with BCG intravesical instillation in high-risk non-muscle invasive bladder cancer with HER2 high expression

讲者：谭星亮中山大学肿瘤防治中心

摘要号：TPS895

A clinical trial evaluating the efficacy and safety of disitamab vedotin plus tislelizumab combined with re-TURBT in the treatment of HER-2-high expression (2+-3+) non-muscle invasive bladder cancer at high-risk and very high-risk

讲者：陈剑晖福建医科大学附属协和医院

肾细胞癌、阴茎癌、睾丸癌和尿道癌

摘要号：6

Risk factors of complications after inguinal lymph node dissection in patients with penile cancer

讲者：Yilong Gao 四川大学华西医院

摘要号：8

Apatinib monotherapy for pretreated advanced squamous cell carcinoma of the penis: A phase II trial

讲者：张盛复旦大学附属肿瘤医院

摘要号：481

Observational study of tislelizumab (Tisle) combined with pazopanib in reducing venous tumor thrombus in clear cell renal cell carcinoma with venous invasion

讲者：拜合提亚尔·艾合买提江新疆医科大学第一附属医院

摘要号：500

Safety and efficacy of immune checkpoint inhibitor rechallenge in metastatic fumarate hydratase-deficient renal cell carcinoma: A retrospective study

讲者：Yanfeng Tang 四川大学华西医院

摘要号：504

Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma

讲者：Jie Wu 浙江省肿瘤医院

摘要号：529

Efficacy and safety of SABR with TKI and IO therapy in patients with mRCC

讲者：杨恺惟北京大学第一医院

摘要号：530

Cadonilimab combined with lenvatinib for neoadjuvant therapy in early-stage renal cell carcinoma with indications for partial nephrectomy but high surgical risk: A prospective single-arm phase II clinical trial

讲者：彭毓璐中山大学肿瘤防治中心

摘要号：532

Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: A comparative analysis with axitinib combined with standard-dose toripalimab

讲者：杜君天津医科大学肿瘤医院

摘要号：534

Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study

讲者：龚侃北京大学第一医院

摘要号：542

Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated results from a single-arm, multicentre clinical trial

讲者：黄吉炜上海交通大学医学院附属仁济医院

摘要号：544

Cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) combined with axitinib for the first-line treatment of advanced or metastatic non-clear renal cell carcinoma: A prospective, single-arm, phase Ib/II study

讲者：胡旭四川大学华西医院

摘要号：550

Efficacy of systemic treatments for advanced non-clear cell renal cell carcinoma: A single-arm systematic review and meta-analysis

讲者：Xinyuan Wei 四川大学华西医院

摘要号：556

The evaluation of therapeutic outcomes of percutaneous US/CT-guided bipolar radiofrequency ablation for small renal masses under local anesthesia

讲者：Yifan Sun 南京鼓楼医院

摘要号：557

A phase II clinical study of camrelizumab plus apatinib in combination with stereotactic body radiotherapy (SBRT) for advanced non-clear cell renal cell carcinoma (nccRCC)

讲者：Xinyue Zhang 中山大学肿瘤防治中心

摘要号：563

Prognostic value of preoperative fibrinogen in metastatic clear cell renal cell carcinoma patients undergoing cytoreductive nephrectomy: A propensity score-matched study

讲者：寿建忠中国医学科学院肿瘤医院

摘要号：585

Use of integrated multi-omics analysis to analyze prognostic molecular subtype in collecting duct carcinoma

讲者：Xiaowen Wu 北京大学肿瘤医院

摘要号：TPS613

A prospective, single-center, single-arm clinical study of adjuvant toripalimab combined with axitinib in non-clear renal cell carcinoma (nccRCC) patients with high-risk recurrence factors (IUNU-RC-102)

讲者：刘光香南京鼓楼医院

摘要号：TPS616

VORSIN-RCC: Vorolanib plus sintilimab for advanced renal cell carcinoma after failure of prior immune checkpoint inhibitors-based combination therapy

讲者：Yu Shen 四川大学华西医院

编辑：Lya/Faline

审校：Faline

排版：Faline

执行：Aurora

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。

特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。

Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.